



**This activity is provided by:**



**This activity is supported by educational grants from Pfizer and Jazz Pharmaceuticals.**

- Date**                    **Saturday, September 8, 2018**
- Faculty**                **Laura Zitella, MS, RN, ACNP-BC, AOCN**  
Hematology/Oncology Nurse Practitioner  
Clinical Associate Professor, University of California, San Francisco
- Location**              **JW Marriott Los Angeles LA Live**  
**Los Angeles, CA**

**Target Audience**

This activity has been designed to meet the educational needs of oncology nurses and nurse practitioners involved in the care of patients that experience chemotherapy-induced nausea and vomiting as a result of their treatment.

**Overview**

The landscape of AML treatment is evolving and newer targeted agents may improve outcomes for selected subgroups of patients. Oncology nursing professionals are key members of the care team, providing disease and treatment information, managing adverse effects, and offering emotional support. Knowledge of key management issues for those with AML and the skills to address them is critical in fulfilling this role. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention is also critical in order to reduce the potential for serious adverse events and complications.

**Learning Objectives**

Upon completion of this educational activity, learners should be better able to:

- Review recently approved agents for patients with newly diagnosed and relapsed AML and their implications for patient selection and nursing care
- Evaluate patients with AML receiving treatment with recently approved agents in order to identify early indications of adverse events and implement appropriate interventions
- Outline key education points for the patient and family/caregiver to prevent infection, identify signs of bleeding, and perform other assessments to improve early identification and management of adverse events

## Activity Agenda

### **Segment 1: Review recently approved agents for patients with newly diagnosed and relapsed AML and their implications for patient selection and nursing care**

- Limitations of current treatment options
- Research and therapeutic advances suggest some patients with AML could benefit from targeted therapy
- Agents recently approved for specific subgroups of patients with AML

### **Section 2: Evaluate patients with AML receiving treatment with recently approved agents in order to identify early indications of adverse events and implement appropriate interventions**

- Specific nursing considerations
- Case example(s) of how to assess and monitor patients relative to significant toxicities?

### **Section 3: Outline key education points for the patient and family/caregiver to prevent infection, identify signs of bleeding, and perform other assessments to improve early identification and management of adverse events**

- Care plan

Questions and Answers

**To promote active learning and engage learners, audience polling questions and a discussion case have been incorporated into the activity design.**

## Accreditation and Credit Statements

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Provider is certified by the California Board of Nursing. American Academy of CME, Inc. designates this educational activity for 1.0 contact hour (pharmacotherapeutic contact hour .7).

### *California*

Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.0 contact hours.

## Method of Participation

There are no fees for participating/receiving CE credit for this activity. In order to receive CE contact hours, learners must:

- 1) Review the CE information including the learning objectives and disclosure statements;
- 2) Attend the activity and document attendance;
- 3) Complete and return the course evaluation form

Upon successfully completing the activity evaluation, your certificate will be email to you in approximately 30 days.

## Disclosures

According to the disclosure policy of American Academy of CME, Inc., all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosures will be made known to participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy or American Nurses Credentialing Center's Commission on Accreditation. This activity is intended as a supplement to

existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

### **Course Director**

Laura Zitella, MS, RN, ACNP-BC, AOCN discloses the following relationships:

Advisory Board – for scientific information (AbbVie, Amgen, Array BioPharma Inc, Astra Zeneca, Gilead)

Shareholder- Kite Pharmaceuticals

### **Planning Committee**

John JD Juchniewicz, MCIS, CHCP, Paul J. Minitzer, MS, Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner, and Wendy Gloffke, PhD, American Academy of CME: No relevant financial relationships with any commercial interests.

### **Off-Label Usage Disclosure**

This educational activity may contain discussion of published and/or investigational uses of agents not indicated by the FDA. Faculty have been asked to disclose off-label and/or investigational uses if they are mentioned. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Academy of CME. Before using any medication, learners should consult primary references and full prescribing information. Please refer to official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, learners should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity. American Academy of CME requires faculty to provide the level of evidence for patient care recommendation made during their presentations.

Per regulatory guidelines, the educational grant used to support this activity may only be used for medical professionals attending the presentation. Our grant funding does not allow for participation by non-healthcare providers and/or guests. If you have questions or comments about this activity, contact [CEServices@academycme.org](mailto:CEServices@academycme.org).

### **Faculty Biography**

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, is the Lead Advanced Practice Provider and Nurse Practitioner for inpatient hematology/oncology at Stanford Health Care and Stanford Cancer Institute. Ms. Zitella received her Masters of Science and Bachelors of Science in Nursing from the University of Illinois. She is certified as an Acute Care Nurse Practitioner and Advanced Oncology Certified Nurse. Ms. Zitella leads an inpatient medical service of nurse practitioners responsible for the care of hospitalized patients with malignancies. She is actively involved in program development, evidence-based practice, electronic medical record and quality improvement initiatives at the Stanford Cancer Institute and the Stanford Center for Advanced Practice. She also serves as Clinical Associate Professor in the Department of Physiological Nursing at the University of California San Francisco.

Ms. Zitella is a published author, presenter, and educator on various oncology topics, particularly hematologic malignancies, the administration of chemotherapy and biotherapy, and supportive care topics such as infection, anemia, and oncologic emergencies. She also is an active member of the Oncology Nursing Society, the Advanced Practitioner Society of Hematology and Oncology, and the American Association of Nurse Practitioners.